Skip to content

Effectiveness of Ayurvedic Formulation Patanjali Haemogrit Vital in subjects with Anemia.

Efficacy of Indian Ayurvedic Formulation Haemogrit Vital in subjects with Anemia: A Single-Arm, Open-Label, Prospective, Interventional Study - NIL

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/09/057653
Enrollment
100
Registered
2023-09-14
Start date
Unknown
Completion date
Unknown
Last updated
2023-10-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: D509- Iron deficiency anemia, unspecified

Interventions

None listed

Sponsors

Patanjali Research Foundation governed by Patanjali Research Foundation Trust
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Adult male and female population having mild or moderate anemia defined as follows: Hb levels: Female: mild: 11.0-11.9 g/dl, moderate: 8.0–10.9 g/dl.; Males: mild: 11.0–12.9 g/dl, moderate: 8.0–10.9g/dl. 2.Subjects aged from 18 years and above. 3. Signed informed consent prior to study specific procedures. 4.Availability and willingness to complete all study visits and procedures per protocol.

Exclusion criteria

Exclusion criteria: 1. Having Sickle Cell Anemia, Thalassemia Minor, Pernicious Anemia, Aplastic Anemia. 2. Having Hemophilia, & Other Hemolytic diseases. 3. Erythropoietin treatment within 8 weeks prior to the screening visit. 4. Pregnancy or Breast Feeding. 5. Chronic inflammation eg. RA, AS, Gastro-intestinal disorders eg. UC, IBD, Hemorrhoids. 6. Having Chronic Kidney Disease, Chronic Liver Disease, Psychiatric Disorders. 7. Any Malignant Conditions eg. Myeloma, Lymphoma etc. 8. Intake of iron preparations 4 weeks prior to screening. 9. Known hypersensitivity to any excipients of the intervention. 10. Participation in any other interventional trial within 4 weeks prior to screening. 11. Patients planning surgery within the trial phase or receiving a blood transfusion a week prior to the screening visit. 12. Inability to fully comprehend and/or perform study procedures or provide written consent in the Investigator’s opinion. 13. Any other medical condition that, in the opinion of the investigator, makes the patient incompetent to participate in the trial or places the patient at potential risk, e.g. any chronic comorbidity.

Design outcomes

Primary

MeasureTime frame
•Mean change from baseline in Hemoglobin levels at Day 60.Timepoint: Baseline, Day 30, Day 60

Secondary

MeasureTime frame
Mean Changes in MFSI-SF, BFI, SF-12, PSQI & also the changes from baseline to Day 60 in CBC Count.Timepoint: Baseline, Day 30, Day 60

Countries

India

Contacts

Public ContactDr Bhawna sharma

Patanjali Research Foundation

drdevasenabamsmd@gmail.com07012421624

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026